Delivery Order SPE2DP20D0002-SPE2DP25F8220
Award Date 6/16/25
Potential Completion Date 6/24/25
Potential Value $330K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- The U.S. Department of Defense, through the Defense Logistics Agency Troop Support Medical, awarded a delivery order valued at $330,313.86 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, awarded on July 14, 2025, with a completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a firm-fixed-price delivery order valued at $165,156.93 to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. The contract was awarded on May 12, 2025, with an ultimate completion date of May 20, 2025, and is being performed at Teva's facility in Parsippany, New Jersey. This delivery order was issued without a set-aside designation, allowing competition among all qualified vendors. The...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...